Study guide

6.1 Prescription Evaluation

APC Intern Written Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Pathway to General Registration 1.3 Restricted Open-Book Strategy (AMH & APF) 1.4 Scoring, Results & Appeals

2 Legal Framework: PBS & Medicine Schedules

2.1 PBS, Authority Prescriptions & Special Access Scheme 2.2 Schedules 2 & 3 (Pharmacy & Pharmacist Only Medicines) 2.3 Schedules 4 & 8 (Prescription Only & Controlled Drugs)

3 Legal Framework: Privacy, National Law & Pharmacy Board

3.1 Privacy, Confidentiality & Patient Rights 3.2 Health Practitioner National Law & Registration 3.3 Pharmacy Board Codes, Guidelines & Standards

4 Patient-Centred Medication Management

4.1 Assessing Clinical Situations & Treatment Options 4.2 Patient Factors: Adherence, Efficacy & Safety 4.3 Drug & Dosage-Form Factors 4.4 Culturally Responsive Medication Management

5 Primary Care & Judicious Use of Medicines

5.1 Primary Care & OTC Assessment 5.2 Judicious Use of Antimicrobials & High-Risk Agents 5.3 Non-Pharmacological Options & Evidence-Based OTC Choices

6 Dispensing & Clinical Appropriateness

6.1 Prescription Evaluation 6.2 Clinical Appropriateness Checks 6.3 Labelling, Packaging & Dispensing Standards 6.4 Communicating with Prescribers & Documenting Changes

7 Counselling & Acute Care

7.1 Patient-Centred Counselling 7.2 Confirming Understanding & Lifestyle Counselling 7.3 Acute Illness, Injury & Emergency Response

8 Therapeutics: Cardiovascular & Endocrine

8.1 Hypertension & Heart Failure 8.2 Ischaemic Heart Disease & Anticoagulation 8.3 Diabetes Medicines 8.4 Thyroid & Lipid Disorders

9 Therapeutics: Infection, Respiratory & Gastrointestinal

9.1 Anti-Infectives & Infection Management 9.2 Asthma & COPD 9.3 Gastrointestinal & Hepatic Conditions 9.4 Vaccination & Travel Health

10 Therapeutics: Neurology, Psychiatry & Pain

10.1 Epilepsy & Movement Disorders 10.2 Depression, Anxiety & Psychosis 10.3 Pain Management & Opioids 10.4 Migraine & Common Analgesics

11 Therapeutics: Special Populations & Systems

11.1 Women's Health, Contraception & Pregnancy 11.2 Dermatology, Ophthalmology & ENT 11.3 Renal/Hepatic Impairment & Dose Adjustment

12 Therapeutics: Rheumatology, Haematology, Urology, Oncology & Toxicology

12.1 Rheumatology: Gout, Osteoarthritis & Inflammatory Arthritis 12.2 Haematology: Anaemias & Blood Safety Monitoring 12.3 Urology & Men's Health 12.4 Oncology Support & Oral Anticancer Medicines 12.5 Toxicology & Poisoning Management

13 Monitoring: Clinical Review

13.1 Clinical Review Process 13.2 Interpreting Laboratory & Clinical Monitoring 13.3 Recommending Treatment Modifications

14 Monitoring: Safety & Adverse Drug Reactions

14.1 Adverse Drug Reactions & Reporting 14.2 Allergies, Sensitivities & Cross-Reactivity 14.3 High-Risk Medicines Monitoring

15 Compounding Medicines

15.1 Determining Required Formulations 15.2 Compounding Standards & Quality 15.3 Patient-Specific Preparations

16 Pharmaceutical Calculations

16.1 Dosage Calculations 16.2 Concentrations, Dilutions & Alligation 16.3 Half-Life & Basic Kinetic Calculations

17 Promote Health & Well-Being

17.1 National & Local Health Priorities 17.2 Screening Programs & Pharmacist Role 17.3 Culturally Responsive Promotion & Self-Sufficiency

6.1 Prescription Evaluation

Key Takeaways Explain This Topic AI

A lawful supply decision requires both a complete, authentic prescription and schedule-compliant particulars — missing critical elements mean clarify or withhold, never guess.

Electronic prescriptions authenticate differently from paper scripts, but clinical and schedule obligations still apply to every supply.

Schedule 8 prescriptions usually need extra particulars and tighter authenticity checks because of dependence and diversion risk.

Owings and partial supplies must preserve remaining quantity, patient safety, and claim integrity; PBS rules and private rules are separate pathways.

Detecting alterations, forgeries, and mismatched patient–medicine details is a core professional duty under Standard 3.2.3.

Last updated: August 2026

6.1 Prescription Evaluation

Quick Answer: Before you label a medicine, evaluate the prescription as a legal and clinical instrument . Confirm who prescribed, for whom, what (drug, strength, form), how much, how to take it, when it was written, and that authentication (signature or electronic equivalent) is valid. Add Schedule 8 (S8) extra checks when needed, detect alterations, decide PBS versus private , and manage owing/partial supply without breaking remaining quantity or claim rules. If critical elements are missing or unsafe, clarify with the prescriber or withhold supply.

Dispensing under National Competency Standard 3.2.3 is not a packing task. It is a professional process that starts with prescription evaluation : is this document (or electronic token) complete, authentic, current, and capable of supporting a safe supply decision?

Why evaluation comes before everything else

A medicine can only be supplied lawfully when the authority to supply is established. In Australian practice that authority is usually a valid prescription (or another lawful authorisation recognised by schedule and jurisdiction). Clinical review, labelling, counselling, and PBS claiming all sit after you know the prescription is fit to act on.

Common exam and practice failures at this step include:

  • Dispensing from incomplete or ambiguous directions
  • Ignoring missing strength, form, or quantity
  • Treating a PBS claim problem as if it fixed a legal defect
  • Supplying S8 medicines on prescriptions that lack required extra particulars
  • Accepting visibly altered paper scripts without investigation
  • Confusing “patient wants it today” with “supply is lawful”
  • Legal completeness — the core particulars

Exact statutory wording differs between states and territories and between paper and electronic prescriptions. For the Intern Written Examination, master national principles : every prescription must identify the who, what, how much, how, and when with enough clarity for safe, auditable supply.

Element What you need Exam red flag if missing/unclear

Prescriber Authorised prescriber identifiable and able to prescribe that medicine Unknown or unauthorised prescriber

  • Patient Clear identity (name ± other identifiers as required) Wrong patient risk, ambiguous identity
  • Drug Active ingredient and/or brand as written; no dangerous ambiguity Could be two different medicines
  • Strength Unambiguous strength (or combination strengths) “Metformin” with no mg
  • Form Tablet, capsule, liquid, patch, inhaler, injection, etc. Oral vs injectable confusion

Dose / directions Clear dosage regimen or administrable instructions “As directed” when not clinically/legally acceptable for that item

  • Quantity Amount to supply (or pack logic that determines quantity) Cannot calculate or verify supply amount
  • Date Date of prescribing; respect currency/expiry rules Out-of-date script under local law
  • Authentication Signature (paper) or compliant electronic authentication Unsigned/unauthenticated order
  • Repeats (if any) Authorised correctly when applicable Inventing repeats not authorised

If a critical element is missing, illegible, or contradictory, do not invent the missing piece . Contact the prescriber for clarification, or refuse supply until remedied. Non-critical ambiguities that do not affect identity of medicine, dose safety, or legality may sometimes be resolved with patient confirmation and documentation — but never invent strength, form, or S8 particulars.

Patient and prescriber identity

Confirm the patient matches the person presenting (or the carer/agent with appropriate authority). Watch for similar names, outdated details, and hospital discharge scripts that may not match community records. For the prescriber, confirm they appear to be a recognised authorised prescriber for that medicine class in context (for example, some restricted medicines require specialist initiation or permit arrangements under state law). When in doubt, verify before supply.

Drug, strength, form, dose, quantity

Treat these as a package :

Drug — Is the medicine clearly specified? Abbreviations and look-alike names are high risk.

Strength — Multi-strength products (e.g. many opioids, anticoagulants, paediatric liquids) demand precision.

Form — Incorrect form can change bioavailability and legal schedule context (e.g. different products).

Dose — Directions must support safe use; unclear frequency or titration needs clarification.

Quantity — Must be consistent with directions, PBS maximum quantities (if PBS), and clinical duration cues.

A classic exam trap is a script that is “almost complete” but omits strength for a multi-strength S4, or quantity for an S8. Almost complete is not complete.

Electronic versus paper prescriptions

Australia’s electronic prescription framework uses tokens and conformant systems rather than a handwritten signature on paper. Principles for exam thinking:

  • Feature Paper concept Electronic concept
  • Authenticity Signature, appearance, paper integrity System authentication, token validity, conformant software
  • Completeness All required fields readable on the form All required data present in the electronic prescription
  • Alteration risk Overwriting, different inks, erasures Unauthorised change is a system/process integrity issue

Repeats / remaining supply Annotations, repeat authorisations Electronic remaining supply and token handling rules

Clinical duty Same Same — e-scripts do not skip clinical or schedule checks

Key point: Moving from paper to electronic changes how authenticity and remaining quantity are managed; it does not remove the pharmacist’s duty to evaluate clinical appropriateness, counselling needs, S8 controls, or PBS versus private pathway correctness.

When an electronic token cannot be retrieved, is already fully dispensed, or data appear incomplete, treat that as a block to supply until resolved through the correct electronic or prescriber pathway — not by improvising a paper substitute without lawful basis.

Schedule 8 extra particulars — principles

S8 controlled drugs attract stricter prescription requirements because of dependence, misuse, and diversion risk. Exact extra fields and wording vary by jurisdiction, but exam-ready principles include:

Heightened identification of patient and prescriber details (often more complete name/address-type particulars than a simple S4)

  • Unambiguous medicine, form, strength, quantity, and directions
  • Date and authentication that meet controlled-drug rules

Limits on what can be altered after writing; many changes require a new prescription or formal amendment pathway

  • Integration with real-time prescription monitoring where applicable (state systems)
  • Safe custody and recording obligations after the clinical decision to supply

PBS listing of an S8 does not soften S8 prescription law. Private S8 supply still requires S8-compliant authority to supply. If S8 particulars are incomplete, do not supply on “we’ll fix the paperwork later” pressure.

Detecting alterations and authenticity concerns

Pharmacists are expected to exercise reasonable diligence against forgery and unauthorised alteration.

Paper red flags (non-exhaustive):

  • Different handwriting or ink for critical fields (quantity, drug name, patient name)
  • Erasures, overwriting, or obvious additions after signature
  • Unusually large quantities or out-of-character doses for the stated indication context

Photocopy quality, missing security features where expected, or generic “clinic” details that cannot be verified

Patient urgency combined with reluctance to allow verification

Electronic / process red flags:

  • Token handling inconsistencies, duplicate presentation attempts, mismatched patient identity
  • Pressure to override system warnings without clinical or technical resolution
  • Requests to “just type it in” without a valid electronic or paper authority

Response pathway: pause supply, verify with the prescriber or system, document concerns, and refuse if authenticity cannot be established. Patient distress does not convert a forged or altered prescription into a legal one.

Owing and partial supply concepts

Real pharmacies often cannot supply the full prescribed quantity immediately (stock shortage, pack size mismatch, staged supply for safety).

Principles:

Partial supply — supply less than the full quantity now when clinically and legally appropriate, with a clear plan for the remainder.

Owing — document and track the balance still due so the patient receives remaining medicine without creating a second full claim or double-supply error.

Remaining quantity integrity — electronic systems and paper annotations must accurately reflect what has been supplied and what remains.

Clinical safety — partial supply is not a reason to skip counselling or monitoring alerts (e.g. opioids, antibiotics, anticoagulants).

Patient communication — explain what was supplied, when the balance should be available, and any interim risk (running out of essential medicine).

Never “complete” an owing by inventing a new prescription. Never claim PBS for a full quantity when only a partial quantity was supplied. Align stock movement, label quantity, counselling, and claim with the actual supply event.

PBS versus private — evaluate the pathway

Prescription evaluation includes deciding the funding pathway , which is separate from schedule legality.

Pathway Meaning Evaluation focus

PBS Subsidised Pharmaceutical Benefits Scheme supply when eligibility and item rules are met Patient PBS eligibility, item restriction/authority, quantity/repeats, streamlined or written authority where required, brand substitution rules

Private Non-PBS supply on a valid prescription Schedule validity still required; price is private; no PBS claim

Important distinctions:

A prescription may be legally valid for private S4/S8 supply even if it does not meet a particular PBS authority rule — but then it is not claimable as that PBS item.

Conversely, a PBS claim cannot legitimise a schedule-invalid or incomplete prescription.

Visitors, overseas patients, or non-eligible people may still receive private supply of prescription medicines when the prescription and schedule rules are met.

Authority Required items (including STREAMLINED codes) need compliant authority information for PBS supply; absence of authority does not automatically create private legality if the underlying prescription is defective for other reasons.

  • Practical evaluation workflow (exam model)
  • Authenticate — paper integrity or electronic token/system validity
  • Identify — patient and authorised prescriber
  • Complete particulars — drug, strength, form, dose, quantity, date, authentication, repeats
  • Schedule overlay — S4 vs S8 (and monitored medicines) extra requirements
  • Pathway — PBS (with authority rules if relevant) vs private
  • Supply logistics — full, partial, or owing with accurate remaining quantity
  • Escalate — clarify, amend, or withhold when any critical step fails

Only after this evaluation should you move into clinical appropriateness checks (Section 6.2), labelling (Section 6.3), and prescriber communication (Section 6.4).

Exam mindset

Intern Written items often present a script that looks routine until one element fails: missing strength, expired date, S8 particulars incomplete, electronic token already used, PBS authority absent, or a suspected alteration. Choose the action that protects legality and patient safety — clarify or withhold — rather than the option that prioritises speed or customer satisfaction alone.